Form 4: Dianthus Therapeutics, Inc. /DE/ Director Sells Shares
Insider Transaction (Form 4)
Simon Read, a Director of Dianthus Therapeutics, Inc. /DE/, sold 2,778 shares of common stock on August 19, 2026 for $117.55 per share.
Summary
- Option exercise/conversion: acquired 2,778 Common Stock at $18.36 ($51,004) on August 19, 2026; holds 2,778 after (Direct).
- Open-market sale: disposed of 2,778 Common Stock at $117.55 ($326,554) on August 19, 2026 (Direct).
- Option exercise/conversion: disposed of 2,778 Stock Option (Right to Buy) on August 19, 2026; holds 19,445 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $326,554 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Simon Read — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Option exercise/conversion | Common Stock | 2,778 | $18 | $51.0K | 2,778 |
| 2026-08-19 | Open-market sale | Common Stock | 2,778 | $118 | $326.6K | 0 |
| 2026-08-19 | Option exercise/conversion | Stock Option (Right to Buy) | 2,778 | — | — | 19,445 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Option exercise/conversion (2,778 shares) |
| 2026-08-19 | Open-market sale (2,778 shares) |
| 2026-08-19 | Option exercise/conversion (2,778 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Simon Read
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.